Roivant Sciences LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have updated their Schedule 13G filing to reflect their beneficial ownership of Roivant Sciences Ltd. common shares.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed a Schedule 13G, reporting beneficial ownership of Roivant Sciences Ltd. common shares.
NASDAQ
Vivek Ramaswamy has filed an amendment to his Schedule 13G, reporting beneficial ownership of 25,534,970 common shares in Roivant Sciences Ltd.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Roivant Sciences Ltd following an internal corporate realignment.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 10.3% of Roivant Sciences Ltd.'s common stock as of February 27, 2026.
NASDAQ
Vivek Ramaswamy has increased his beneficial ownership in Roivant Sciences Ltd. to 6.8% of common shares, totaling 48,428,792 shares.
NASDAQ
Morgan Stanley and its subsidiary have reported an 8.0% beneficial ownership in Roivant Sciences Ltd. as of December 31, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Roivant Sciences Ltd. as of December 31, 2025.
NASDAQ
Viking Global Investors LP and its affiliates have reduced their beneficial ownership in Roivant Sciences Ltd. to 3.4% of common shares.
NASDAQ
SoftBank investment entities have disclosed a continued beneficial ownership of 5.8% in Roivant Sciences Ltd., holding over 40 million common shares.
NASDAQ
Viking Global Investors LP and its affiliates, along with key executives, reported a collective beneficial ownership of 5.02% in Roivant Sciences Ltd. common shares.
NASDAQ
QVT Financial LP has reduced its beneficial ownership in Roivant Sciences Ltd. to 4.30% of common shares.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported beneficial ownership of 5.5% of Roivant Sciences Ltd.'s Common Shares.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting beneficial ownership of 8.2% of Roivant Sciences Ltd.'s common stock.
NASDAQ
SCHEDULE 13G/A: Vivek Ramaswamy Maintains Significant Stake in Roivant Sciences, Discloses Over 11% Beneficial Ownership
Vivek Ramaswamy, a key figure, has filed an amended Schedule 13G disclosing a beneficial ownership of 11.63% in Roivant Sciences Ltd. as of March 31, 2025.
NASDAQ
Vivek Ramaswamy has filed an amended Schedule 13G, disclosing a beneficial ownership of 11.16% in Roivant Sciences Ltd., totaling 82,956,521 common shares as of December 31, 2024.
NASDAQ
Viking Global Investors LP and its affiliated entities, along with key executives, have filed an amended Schedule 13G, reporting a collective beneficial ownership of 6.4% in Roivant Sciences Ltd.'s Common Shares as of March 31, 2025.
NASDAQ
QVT Financial LP has filed an amended Schedule 13G, reporting a 9.22% passive ownership stake in Roivant Sciences Ltd. as of December 31, 2024.
NASDAQ
Multiple SoftBank-affiliated entities have jointly reported a passive beneficial ownership of 8.5% in Roivant Sciences Ltd., totaling 62,057,537 common shares as of December 31, 2024.